Events & Presentations
| Date | Event Details | Remind Me |
|---|---|---|
|
May 4, 2021 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2021 Second Quarter Results
|
| Date | Event Details |
|---|---|
|
Feb 4, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 First Quarter Results
|
|
Dec 12, 2020 12:55 PM EST
|
20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency
View Presentation 1.1 MB
James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine, will deliver an oral presentation titled, “Arrowhead’s approach to gene silencing - ARO-AAT for liver disease in Alpha-1 antitrypsin deficiency”
|
|
Dec 10 - Dec 12, 2020
|
National Lipid Association Scientific Sessions 2020
NLA 2020 ARO-APOC3 757.8 KB
NLA 2020 ARO-ANG3 1.1 MB
|
|
Dec 1 - Dec 3, 2020
|
32nd Piper Jaffray Annual Virtual Healthcare Conference
December 2, 2020 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. Recording is available on demand
|
|
Nov 23, 2020 4:30 PM EST
|
Arrowhead Pharmaceuticals 2020 Year End Results
Prepared Remarks 194.2 KB
|
|
Nov 19, 2020 1:30 PM EST
|
ARO-ANG3 KOL Webinar
ARO-ANG3 KOL Webinar Slides 2.1 MB
KOL: Ira Goldberg, M.D., New York University Langone School of Medicine
|
|
Nov 18, 2020 11:30 AM EST
|
ARO-APOC3 KOL Webinar
KOL: Christie Ballantyne, M.D., Baylor College of Medicine
|
|
Nov 17 - Nov 19, 2020
|
Jefferies Virtual London Healthcare Conference
November 19, 2020, 2:40 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.
|
|
Nov 13 - Nov 16, 2020
|
The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers
Authors: Pavel Strnad, et al. Publication Number: LP14 Session: Late-breaking Abstract Posters |
|
Nov 13 - Nov 17, 2020
|
American Heart Association (AHA) Scientific Sessions 2020
Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a) |